Clinical Trial Update: Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety of pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2022-01-10